To view or add a comment, sign in Napo's Parent Company Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program #JAGX To view or add a comment, sign in The industry continues to collaborate in an effort to reach more patients and consumers
Abrupt discontinuation is not recommended, particularly at higher maintenance doses
Researchers are responsible for compliance with all applicable institutional, state, and federal regulations
In a Phase II trial, patients in the Mazdutide group saw a weight decrease between 5% and 22.5%, with a notable proportion of patients across different dosage groups achieving at least a 10% or even higher degree of weight reduction
Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimers disease
Zhang X, Lu Z, Ren X, Chen X, Zhou X, Zhou X, et al